Research Capital analyst Andre Uddin maintained a “Buy” rating and C$5.55 price target on Medexus Pharmaceuticals (Medexus Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSXV:MDP) in a June 26 note, following fourth-quarter fiscal 2025 results that showed stabilizing revenue and progress in reducing debt. Medexus reported Q4 revenue of $24.8-million, nearly matching Uddin’s estimate of […]
Research Capital analyst Andre Uddin maintained a “Speculative Buy” rating and C$0.60 price target on Sernova Biotherapeutics (Sernova Biotherapeutics Stock Quote, Chart, News, Analysts, Financials TSXV:SVA) in a June 16 report, citing strong early clinical results and a promising pipeline, but warning the company will need to secure more funding in the near term. Sernova […]
Share
Tweet
Share
